Galantamine (Gala) v placebo for suspected Alzheimer's disease*
| Scales assessed at 6 months | Gala dose | Gala | Placebo | RBI (95% CI) | NNT (CI) |
|---|---|---|---|---|---|
| *CIBIC-plus=Clinician's Interview Based Impression of Change plus Caregiver Input showing no change or improvement; ADAS-cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale >4 points improvement. Other abbreviations defined in glossary; RBI, NNT, and CI calculated from data in article. | |||||
| †Weighted event rates (≥1 study). | |||||
| CIBIC-plus | 16 mg/day | 68% | 48% | 42% (21 to 67) | 6 (4 to 10) |
| 24 mg/day | 67%† | 50%† | 32% (20 to 47) | 7 (5 to 10) | |
| 32 mg/day | 51%† | 37%† | 35% (19 to 54) | 8 (6 to 14) | |
| ADAS-cog | 16 mg/day | 36% | 20% | 82% (32 to 151) | 6 (5 to 13) |
| 24 mg/day | 34%† | 18%† | 82% (3 to 151) | 7 (5 to 13) | |
| 32 mg/day | 35% | 15% | 129% (52 to 248) | 6 (4 to 10) | |
